Revance Therapeutics, Inc. (NASDAQ:RVNC) has been assigned a $50.00 price target by equities researchers at Cantor Fitzgerald in a research report issued to clients and investors on Thursday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price would suggest a potential upside of 92.68% from the company’s previous close.

RVNC has been the subject of a number of other reports. Zacks Investment Research upgraded shares of Revance Therapeutics from a “hold” rating to a “buy” rating and set a $26.00 target price for the company in a research report on Wednesday, August 30th. Piper Jaffray Companies reiterated a “buy” rating and issued a $28.00 target price on shares of Revance Therapeutics in a research report on Friday, October 27th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $35.50.

Revance Therapeutics (NASDAQ:RVNC) opened at $25.95 on Thursday. Revance Therapeutics has a twelve month low of $15.85 and a twelve month high of $28.75.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.95) by ($0.06). The company had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.05 million. Revance Therapeutics had a negative net margin of 37,161.00% and a negative return on equity of 67.85%. The business’s revenue for the quarter was up .0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.64) earnings per share. equities research analysts forecast that Revance Therapeutics will post -3.73 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Revance Therapeutics, Inc. (RVNC) PT Set at $50.00 by Cantor Fitzgerald” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at

In related news, CEO L Daniel Browne sold 22,800 shares of the firm’s stock in a transaction dated Wednesday, August 23rd. The shares were sold at an average price of $22.76, for a total transaction of $518,928.00. Following the completion of the sale, the chief executive officer now directly owns 178,850 shares in the company, valued at $4,070,626. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Lauren P. Silvernail sold 11,164 shares of the firm’s stock in a transaction dated Thursday, October 12th. The stock was sold at an average price of $26.67, for a total transaction of $297,743.88. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 59,226 shares of company stock valued at $1,464,618. 18.86% of the stock is owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC acquired a new stake in Revance Therapeutics during the third quarter worth about $144,000. Legal & General Group Plc increased its position in Revance Therapeutics by 8.1% during the second quarter. Legal & General Group Plc now owns 5,815 shares of the biopharmaceutical company’s stock worth $152,000 after purchasing an additional 438 shares during the last quarter. Bank of America Corp DE boosted its stake in Revance Therapeutics by 29.5% during the first quarter. Bank of America Corp DE now owns 7,247 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 1,651 shares during the period. Trexquant Investment LP purchased a new position in Revance Therapeutics during the second quarter worth about $231,000. Finally, Voya Investment Management LLC purchased a new position in Revance Therapeutics during the second quarter worth about $274,000. Hedge funds and other institutional investors own 88.70% of the company’s stock.

About Revance Therapeutics

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.